EN DE
Watch Noul Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Noul Co. Ltd. (376930) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Noul Co. Ltd. stock KRW 1,783, price KRW 1,255, upside +42.1%, quality 27 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

NC Noul Co. Ltd. logo Thin data Nov 7, 2026

Noul Co. Ltd.

376930 · KQ
Speculative

The stock costs 30% less than our calculation considers fair.

Fair value 1,783 KRW · Undervalued
Low debt
Mixed Growth (revenue 5y +76.9 %/yr in KRW)
Revenue last quarter 28% below a year ago.
Quality 27/100
Negative free cash flow
Trails peers (3/8)
Narrow moat 8/100
Thin data
Watch Noul Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

34,961 KRW 1,219 KRW Fair Value 1,783 KRW Mar 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

56‑month range 1,219 KRW – 34,961 KRW · fair‑value band 1,177 KRW – 2,229 KRW · the 1,255 KRW price screens below the 1,783 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Noul Co. in your weekly email

Every Wednesday you see whether Noul Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Noul Co.,Ltd. engages in the in-vitro diagnosis and remote diagnosis business worldwide. It offers miLab, an AI-based blood diagnostic medical device that automates sample preparation, imaging, and analysis.

Show moreShow less

The company also provides malaria diagnostics, blood cell morphology analysis, cancer morphology, immunohistochemistry services, and digital cervical cell analysis solution. Noul Co.,Ltd. was incorporated in 2015 and is headquartered in Yongin-si, South Korea.

Stock analysis

Noul Co. Ltd. (376930) currently trades at 1,255 KRW, while our model-based Fair Value estimate is 1,783 KRW, implying the stock looks roughly 30% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 1,177 KRW (bear) to 2,229 KRW (bull), the price of 1,255 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Noul Co. Ltd. reported revenue of 5.1B KRW in FY2025 versus 1.5B KRW in FY2021, a compound +36.5%/yr. Reported net income was −20.0B KRW in FY2025.

Key figures

Market cap 16.7B KRW (≈ $12.4M) Micro · P/S ratio 4.57 · EPS (TTM) −1,917 KRW · Return on equity −145% · Return on assets (EBIT) −51.7% (5-year average) · Operating margin −476% · Revenue (TTM) 3.7B KRW · Revenue growth (YoY) −28.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (medium confidence).

What moves the price

The share trades about 91% below its 52-week high and 3% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 42%, 376930 screens cheaper than that median.

Fair Value models

Bear 1,177 KRW Fair Value 1,783 KRW Bull 2,229 KRW
Price 1,255 KRW · Upside +42.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1,177 KRW 1,783 KRW 2,229 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,177 KRW 1,783 KRW 2,229 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 99
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 9
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+219.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.9%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,460.8% (2020) → −392.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 376930, get fair value alerts →

Compare Noul Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside +42.1% · Top 25%
Profitability
Return on assets −50.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −28.0% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.65× · Cheapest 25%
P/S (12 months) 4.57× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)89 · sector 0
FUTURE (revenue growth)0 · sector 39
PAST (return on equity)0 · sector 15
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs 376930
IQVIA Holdings IQV $271.83 $299.01 +10% vs 376930
Illumina, Inc ILMN $213.13 $234.44 +10% vs 376930
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs 376930
Danaher Corporation DHR $230.25 $209.18 −9% vs 376930
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs 376930
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs 376930
Agilent Technologies, Inc A $174.76 $64.53 −63% vs 376930
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs 376930
Waters Corporation WAT $457.60 $91.26 −80% vs 376930

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Noul Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Noul Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/376930

Frequently asked questions

Is Noul Co. Ltd. (376930) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 1,783 KRW versus a price of 1,255 KRW, about +42% upside (undervalued).
What is the fair value of 376930?
Our model-based fair value for Noul Co. Ltd. is 1,783 KRW (as of Nov 7, 2026), built from audited fundamentals. The current price: 1,255 KRW.
What is the quality score of 376930?
Noul Co. Ltd. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Noul Co. Ltd. (376930)?
Our model-based price target is the fair value of 1,783 KRW (as of Nov 7, 2026) from 1 valuation models. Cautious scenario 1,177 KRW, optimistic scenario 2,229 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Noul Co. Ltd. stock forecast for 2026?
Our models put fair value at 1,783 KRW, about +42% upside versus a price of 1,255 KRW (undervalued). Cautious scenario 1,177 KRW, optimistic scenario 2,229 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Noul Co. Ltd. (376930)?
Noul Co. Ltd. reported trailing-twelve-month revenue of about 3.7B KRW (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Noul Co. Ltd. (376930)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Noul Co. Ltd. it is 1,783 KRW per share (as of Nov 7, 2026), against a price of 1,255 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Noul Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 376930 trades below its calculated fair value: price 1,255 KRW, fair value 1,783 KRW, a gap of about +42% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 376930?
No. The price is what the market pays today (1,255 KRW); the fair value is what the company's own numbers justify (1,783 KRW). For Noul Co. Ltd. the two are 528.13 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Noul Co. Ltd. worth?
The market values Noul Co. Ltd. at about 16.7B KRW (market capitalisation, as of Nov 7, 2026). Per share that is 1,255 KRW; our models calculate a fair value of 1,783 KRW per share.
What do the bullish and bearish scenarios say about 376930?
Our models span a range for Noul Co. Ltd.: cautious scenario 1,177 KRW, base 1,783 KRW, optimistic 2,229 KRW per share (as of Nov 7, 2026, price 1,255 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Noul Co. Ltd. (376930)?
Balance-sheet figures for Noul Co. Ltd. (as of Nov 7, 2026): return on equity −145.4%. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 376930 from its 52-week high?
Noul Co. Ltd. trades at 1,255 KRW, about 91% below its 52-week high of 14,500 KRW and 3% above the low of 1,219 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,783 KRW is for.
Which stocks are comparable to Noul Co. Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Noul Co. Ltd. stock attractive at the current price?
The data as of Nov 7, 2026: price 1,255 KRW, calculated fair value 1,783 KRW (+42%), Quality Score 27/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 376930 calculated?
We run Noul Co. Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,783 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Noul Co. Ltd. currently trades 30% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Noul Co. Ltd. (376930)?
The closing price on Nov 6, 2026 was 1,255 KRW. Our model-based fair value is 1,783 KRW, about +42% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Noul Co. Ltd. right now?
The large discount to fair value meets weak quality (27/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,177 KRW to 2,229 KRW) leaves room in how you read the outcome.

Key figures of Noul Co. Ltd.

How large is the market capitalisation of Noul Co. Ltd. (376930)?
The market capitalisation of Noul Co. Ltd. is 16.7B KRW (≈ $12.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Noul Co. Ltd. (376930)?
The price-to-sales ratio of Noul Co. Ltd. is 4.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Noul Co. Ltd. (376930)?
Earnings per share at Noul Co. Ltd. are −1,917 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Noul Co. Ltd. (376930)?
The return on equity (ROE) of Noul Co. Ltd. is −145% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Noul Co. Ltd. (376930)?
On an EBIT basis the return on assets of Noul Co. Ltd. is −51.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Noul Co. Ltd. (376930)?
The operating margin of Noul Co. Ltd. is −476% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Noul Co. Ltd. (376930)?
Revenue at Noul Co. Ltd. is growing −28.0% versus a year earlier (3y avg +111%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Noul Co. Ltd. (376930) generate?
The free cash flow of Noul Co. Ltd. is −23.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Noul Co. Ltd. (376930) carry?
The net debt of Noul Co. Ltd. is 4.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Noul Co. Ltd. in the live analysis

One click puts Noul Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.